ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

Blood

Volumn 125, Issue 25, 2015, Pages 3937-3948

  Alemdehy, Mir Farshid ^a   Haanstra, Jurgen R ^a   De Looper, Hans W J ^a   Van Strien, Paulina M H ^a   Verhagen Oldenampsen, Judith ^a   Caljouw, Yvette ^a   Sanders, Mathijs A ^a   Hoogenboezem, Remco ^a   De Ru, Arnoud H ^b   Janssen, George M C ^b   Smetsers, Stephanie E ^c   Bierings, Marc B ^c,d   Van Veelen, Peter A ^b   Von Lindern, Marieke ^a   Touw, Ivo P ^a   Erkeland, Stefan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d DCOG Dutch Childhood Oncology Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 139 3P; MICRORNA 199A 3P; UNCLASSIFIED DRUG; DNA-BINDING PROTEINS; ENDONUCLEASES; ERCC1 PROTEIN, MOUSE; MICRORNAS; MIRN139 MICRORNA, MOUSE; MIRN199 MICRORNA, MOUSE; TUMOR SUPPRESSOR PROTEIN P53;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DEPRESSION; CANCER SUSCEPTIBILITY; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; GENE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUR GENE; MALIGNANT TRANSFORMATION; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRDX6 GENE; PRIORITY JOURNAL; RUNX1 GENE; SUZ12 GENE; TUMOR SUPPRESSOR GENE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DEFICIENCY; DISEASE MODELS, ANIMAL; DNA REPAIR; GENETICS; HEMATOPOIETIC STEM CELLS; LEUKEMIA; METABOLISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HEMATOPOIETIC STEM CELLS; LEUKEMIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84935031432     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-612507     Document Type: Article

References (61)

1. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008;22(3):141-153.
2. Parikh S, Bessler M. Recent insights into inherited bone marrow failure syndromes. Curr Opin Pediatr. 2012;24(1):23-32.
3. Bakker ST, Passegué E. Resilient and resourceful: genome maintenance strategies in hematopoietic stem cells. Exp Hematol. 2013;41(11):915-923.
4. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3):101-122.
5. Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. J Pathol. 2012;226(2):326-337.
6. Kashiyama K, Nakazawa Y, Pilz DT, et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am J Hum Genet. 2013;92(5):807-819.
7. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012;122(11):3799-3806.
8. Kim H, D'Andrea AD. Regulation of DNA crosslink repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26(13):1393-1408.
9. Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43(2):138-141.
10. Kim Y, Spitz GS, Veturi U, Lach FP, Auerbach AD, Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood. 2013;121(1):54-63.
11. Hodskinson MR, Silhan J, Crossan GP, et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol Cell. 2014;54(3):472-484.
12. Klein Douwel D, Boonen RA, Long DT, et al. XPF-ERCC1 acts in Unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol Cell. 2014;54(3):460-471.
13. Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92(5):800-806.
14. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43(2):142-146.
15. Rahn JJ, Adair GM, Nairn RS. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen. 2010;51(6):567-581.
16. Parmar K, Kim J, Sykes SM, et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells. 2010;28(7):1186-1195.
17. Tulpule A, Lensch MW, Miller JD, et al. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood. 2010;115(17):3453-3462.
18. Verhagen-Oldenampsen JH, Haanstra JR, van Strien PM, Valkhof M, Touw IP, von Lindern M. Loss of ercc1 results in a time- and dose-dependent reduction of proliferating early hematopoietic progenitors. Anemia. 2012;2012:783068.
19. Prasher JM, Lalai AS, Heijmans-Antonissen C, et al. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice. EMBO J. 2005;24(4):861-871.
20. Du W, Erden O, Pang Q. TNF-α signaling in Fanconi anemia. Blood Cells Mol Dis. 2014;52(1):2-11.
21. Svahn J, Lanza T, Rathbun K, et al. p38 mitogen-activated protein kinase inhibition enhances in vitro erythropoiesis of Fanconi anemia, complementation group A-deficient bone marrow cells. [published online ahead of print December 19, 2014]. Exp Hematol.
22. Ceccaldi R, Parmar K, Mouly E, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36-49.
23. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27-37.
24. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362(6423):849-852.
25. Weeda G, Donker I, de Wit J, et al. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr Biol. 1997;7(6):427-439.
26. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997;94(2):569-574.
27. Wölfler A, Danen-van Oorschot AA, Haanstra JR, et al. Lineage-instructive function of C/EBPα in multipotent hematopoietic cells and early thymic progenitors. Blood. 2010;116(20):4116-4125.
28. Meenhuis A, van Veelen PA, de Looper H, et al. MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. Blood. 2011;118(4):916-925.
29. McWhir J, Selfridge J, Harrison DJ, Squires S, Melton DW. Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nat Genet. 1993;5(3):217-224.
30. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431(7011):997-1002.
31. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28(16):5082-5092.
32. Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell. 2010;40(2):205-215.
33. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172-1187.
34. de Koning JP, Soede-Bobok AA, Ward AC, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene. 2000;19(29):3290-3298.
35. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
36. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533-542.
37. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309(5740):1573-1576.
38. Vanderwerf SM, Svahn J, Olson S, et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood. 2009;114(26):5290-5298.
39. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11(7):467-480.
40. Quentin S, Cuccuini W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood. 2011;117(15):e161-e170.
41. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004;21(6):853-863.
42. Wagner K, Zhang P, Rosenbauer F, et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA. 2006;103(16):6338-6343.
43. Mu P, Han YC, Betel D, et al. Genetic dissection of the miR-17-92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23(24):2806-2811.
44. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1(1):20-26.
45. Freie B, Li X, Ciccone SL, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood. 2003;102(12):4146-4152.
46. Houghtaling S, Granville L, Akkari Y, et al. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res. 2005;65(1):85-91.
47. Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an antiapoptotic program by HuR. Cell Cycle. 2007;6(11):1288-1292.
48. Ghosh M, Aguila HL, Michaud J, et al. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J Clin Invest. 2009;119(12):3530-3543.
49. 2activities. Antioxid Redox Signal. 2011;15(3):831-844.
50. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276(48):44444-44449.
51. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal. 2008;10(11):1909-1921.
52. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004;15(1):57-67.
53. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180-193.
54. Majewski IJ, Blewitt ME, de Graaf CA, et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 2008;6(4):e93.
55. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330.
56. Lee SJ, Pfluger PT, Kim JY, et al. A functional role for the p62-ERK1 axis in the control of energy homeostasis and adipogenesis. EMBO Rep. 2010;11(3):226-232.
57. Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70(12):5184-5193.
58. Henry JC, Park JK, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403(1):120-125.
59. Wu D, Huang HJ, He CN, Wang KY. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer. 2013;23(7):1191-1197.
60. Wang J, He Q, Han C, et al. p53-facilitated miR-199a-3p regulates somatic cell reprogramming. Stem Cells. 2012;30(7):1405-1413.
61. Río P, Agirre X, Garate L, et al. Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFα regulation and proliferation of hematopoietic progenitor cells. Blood. 2012;119(13):3042-3049.